Launch of arthritis drug biosimilars ramps up US pressure on pricing middlemen – The Frontier Post thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.
Cheaper versions of one of the most costly and widely used arthritis treatments in the U.S. are likely to fuel further scrutiny of the middlemen that negotiate drug prices for most insured.
The launch of eight adalimumab biosimilars so far this year ended Humira s 20-year monopoly, but it s not clear yet if these discounted drugs will save patients money.
Read more about Health News Roundup: Hunger haunts Ethiopia's Tigray region after years of war; EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported and more on Devdiscourse
Cigna Group s Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie s blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday.